Bavarian Nordic could be first on the RSV market in China

A new partnership deal with Nuance Pharma turns Bavarian Nordic’s sights to China. CFO Henrik Juuel opens up about the chance for Bavarian Nordic to be first on the market – a very lucrative position for the firm.

Henrik Juuel, CFO at Bavarian Nordic | Photo: Bavarian Nordic PR

The race to the RSV market is fully underway, and on Monday, Bavarian Nordic began sprinting – at least in the direction of the Chinese market.

Bavarian Nordic announced that it had signed a license and commercialization deal with Shanghai-based biotech company Nuance Pharma for the Danish firm’s RSV vaccine candidate, MVA-BN RSV, for people over the age of 60.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs